Analysts' Actions: HP, VVUS, JNPR, K

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Assurant (AIZ) downgraded at Sterne Agee to Neutral, Sterne Agee said. Valuation call, based on a $52 price target.

Alexion Pharmaceuticals (ALXN) upgraded at UBS to Buy from Neutral, UBS said. $99 price target. Upgrade to buy on PNH, NMO and margins.

Community Health (CYH) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $33 price target. Industry is leveraged to better economic growth.

Ericsson (ERIC) upgraded at JP Morgan to Overweight, JP Morgan said. Expectations are low and the company has been gaining market share.

HCA (HCA) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Company is a market leader and the group appears more attractive.

Human Genome (HGSI) downgraded at Collins Stewart from Buy to Neutral, Collins Stewart said. $10 price target. Benlysta sales could fall short of expectations.

Intuit (INTU) rated new Hold at Stifel. Valuation cal.

ITC (ITC) upgraded at Wunderlich from Hold to Buy, Wunderlich said. $85 price target. Company should continue to deliver higher earnings and is trading at an attractive valuation.

Itron (ITRI) downgraded at BofA/Merrill to Underperform, Bank of America/Merrill Lynch said. Valuation call, based on a $45 price target.

Juniper Networks (JNPR) downgraded at FBR from Outperform to Market Perform, FBR Capital Markets said. $21 price target. Seeing more evidence of potential product delays.

Kellogg (K) upgraded at Deutsche to from Hold to Buy, Deutsche Bank said. Pringles purchase could prove to be an inflection point for the company. $57 price target.

Level 3 (LVLT) upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $31 price target. Estimates also boosted, given higher secular demand.

MercadoLibre (MELI) downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. $100 price target. Valuation call, as the stock is up 96% since October.

Principal Financial (PFG) upgraded at Sterne Agee from Neutral to Buy, Sterne Agee said. $35 price target. Company has solid long-term earnings growth potential.